Tags

Type your tag names separated by a space and hit enter

Continued efficacy and safety of subcutaneous apomorphine in patients with advanced Parkinson's disease.
Parkinsonism Relat Disord. 2007 Mar; 13(2):93-100.PR

Abstract

The study purpose was to assess the efficacy of intermittent subcutaneous apomorphine (APO) as acute therapy for off episodes in advanced Parkinson's disease (PD) patients who had previously received APO for 3 months. Patients (n=62) were randomized to receive double-blind treatment with APO at their typically effective dose (TED; APO), APO at their TED+0.2mL (2.0mg; APO+2), placebo at volume equal to their TED (PL), or placebo at volume equal to their TED+0.2mL (PL+2), for a single off episode. Significantly greater improvement in mean Unified PD rating scale motor scores was seen with pooled APO versus pooled placebo 20min after administration (-24.2 vs. -7.4; p<0.0001); the difference was also significant at 10min (p<0.0001). Overall adverse event incidence did not significantly differ between pooled APO and pooled PL. This study supports the long-term use of intermittent APO as effective acute therapy for off episodes in advanced PD patients.

Authors+Show Affiliations

Department of Neurology, University of Tennessee Health Science Center, Memphis, TN, USA. rpeiffer@utmem.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Evaluation Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17055329

Citation

Pfeiffer, Ronald F., et al. "Continued Efficacy and Safety of Subcutaneous Apomorphine in Patients With Advanced Parkinson's Disease." Parkinsonism & Related Disorders, vol. 13, no. 2, 2007, pp. 93-100.
Pfeiffer RF, Gutmann L, Hull KL, et al. Continued efficacy and safety of subcutaneous apomorphine in patients with advanced Parkinson's disease. Parkinsonism Relat Disord. 2007;13(2):93-100.
Pfeiffer, R. F., Gutmann, L., Hull, K. L., Bottini, P. B., & Sherry, J. H. (2007). Continued efficacy and safety of subcutaneous apomorphine in patients with advanced Parkinson's disease. Parkinsonism & Related Disorders, 13(2), 93-100.
Pfeiffer RF, et al. Continued Efficacy and Safety of Subcutaneous Apomorphine in Patients With Advanced Parkinson's Disease. Parkinsonism Relat Disord. 2007;13(2):93-100. PubMed PMID: 17055329.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Continued efficacy and safety of subcutaneous apomorphine in patients with advanced Parkinson's disease. AU - Pfeiffer,Ronald F, AU - Gutmann,Ludwig, AU - Hull,Keith L,Jr AU - Bottini,Peter B, AU - Sherry,James H, AU - ,, Y1 - 2006/10/18/ PY - 2006/01/28/received PY - 2006/06/24/revised PY - 2006/06/29/accepted PY - 2006/10/24/pubmed PY - 2007/5/16/medline PY - 2006/10/24/entrez SP - 93 EP - 100 JF - Parkinsonism & related disorders JO - Parkinsonism Relat Disord VL - 13 IS - 2 N2 - The study purpose was to assess the efficacy of intermittent subcutaneous apomorphine (APO) as acute therapy for off episodes in advanced Parkinson's disease (PD) patients who had previously received APO for 3 months. Patients (n=62) were randomized to receive double-blind treatment with APO at their typically effective dose (TED; APO), APO at their TED+0.2mL (2.0mg; APO+2), placebo at volume equal to their TED (PL), or placebo at volume equal to their TED+0.2mL (PL+2), for a single off episode. Significantly greater improvement in mean Unified PD rating scale motor scores was seen with pooled APO versus pooled placebo 20min after administration (-24.2 vs. -7.4; p<0.0001); the difference was also significant at 10min (p<0.0001). Overall adverse event incidence did not significantly differ between pooled APO and pooled PL. This study supports the long-term use of intermittent APO as effective acute therapy for off episodes in advanced PD patients. SN - 1353-8020 UR - https://www.unboundmedicine.com/medline/citation/17055329/Continued_efficacy_and_safety_of_subcutaneous_apomorphine_in_patients_with_advanced_Parkinson's_disease_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1353-8020(06)00176-3 DB - PRIME DP - Unbound Medicine ER -